Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More
Piramal Enterprises has a presence in custom manufacturing, critical care OTC and financial services. To give a boost to its custom manufacturing operations, the company had acquired Avecia Pharmaceuticals, UK in 2005 and Pfizer's Morpeth facility in... More
AUROBINDO PHARMA | PIRAMAL ENTERPRISES | AUROBINDO PHARMA/ PIRAMAL ENTERPRISES |
|||
---|---|---|---|---|---|
P/E (TTM) | x | 19.2 | -41.9 | - | View Chart |
P/BV | x | 4.2 | 1.4 | 294.7% | View Chart |
Dividend Yield | % | 0.3 | 1.6 | 15.4% |
![]() ![]() |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
AUROBINDO PHARMA Mar-19 |
PIRAMAL ENTERPRISES Mar-19 |
AUROBINDO PHARMA/ PIRAMAL ENTERPRISES |
5-Yr Chart Click to enlarge
|
||
High | Rs | 830 | 3,303 | 25.1% | |
Low | Rs | 527 | 1,797 | 29.3% | |
Sales per share (Unadj.) | Rs | 333.9 | 716.5 | 46.6% | |
Earnings per share (Unadj.) | Rs | 40.4 | 79.7 | 50.6% | |
Cash flow per share (Unadj.) | Rs | 51.8 | 107.9 | 48.0% | |
Dividends per share (Unadj.) | Rs | 2.50 | 28.00 | 8.9% | |
Dividend yield (eoy) | % | 0.4 | 1.1 | 33.5% | |
Book value per share (Unadj.) | Rs | 237.1 | 1,477.5 | 16.0% | |
Shares outstanding (eoy) | m | 585.91 | 184.45 | 317.7% | |
Bonus/Rights/Conversions | ESOP | IS | - | ||
Price / Sales ratio | x | 2.0 | 3.6 | 57.1% | |
Avg P/E ratio | x | 16.8 | 32.0 | 52.6% | |
P/CF ratio (eoy) | x | 13.1 | 23.6 | 55.5% | |
Price / Book Value ratio | x | 2.9 | 1.7 | 165.9% | |
Dividend payout | % | 6.2 | 35.1 | 17.6% | |
Avg Mkt Cap | Rs m | 397,569 | 470,292 | 84.5% | |
No. of employees | `000 | 17.9 | 7.8 | 228.3% | |
Total wages/salary | Rs m | 25,849 | 22,504 | 114.9% | |
Avg. sales/employee | Rs Th | 10,956.9 | 16,899.4 | 64.8% | |
Avg. wages/employee | Rs Th | 1,447.7 | 2,877.7 | 50.3% | |
Avg. net profit/employee | Rs Th | 1,324.3 | 1,879.9 | 70.4% |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 195,636 | 132,153 | 148.0% | |
Other income | Rs m | 1,553 | 3,128 | 49.7% | |
Total revenues | Rs m | 197,189 | 135,281 | 145.8% | |
Gross profit | Rs m | 39,519 | 66,290 | 59.6% | |
Depreciation | Rs m | 6,680 | 5,202 | 128.4% | |
Interest | Rs m | 2,626 | 44,097 | 6.0% | |
Profit before tax | Rs m | 31,767 | 20,119 | 157.9% | |
Minority Interest | Rs m | 27 | 3,194 | 0.8% | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | -881 | 0 | - | |
Tax | Rs m | 7,269 | 8,611 | 84.4% | |
Profit after tax | Rs m | 23,645 | 14,701 | 160.8% | |
Gross profit margin | % | 20.2 | 50.2 | 40.3% | |
Effective tax rate | % | 22.9 | 42.8 | 53.5% | |
Net profit margin | % | 12.1 | 11.1 | 108.6% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 153,645 | 122,742 | 125.2% | |
Current liabilities | Rs m | 120,429 | 310,810 | 38.7% | |
Net working cap to sales | % | 17.0 | -142.3 | -11.9% | |
Current ratio | x | 1.3 | 0.4 | 323.1% | |
Inventory Days | Days | 135 | 23 | 586.1% | |
Debtors Days | Days | 64 | 39 | 164.0% | |
Net fixed assets | Rs m | 103,909 | 116,904 | 88.9% | |
Share capital | Rs m | 586 | 369 | 158.8% | |
"Free" reserves | Rs m | 138,322 | 272,161 | 50.8% | |
Net worth | Rs m | 138,908 | 272,530 | 51.0% | |
Long term debt | Rs m | 1,800 | 270,196 | 0.7% | |
Total assets | Rs m | 264,544 | 856,261 | 30.9% | |
Interest coverage | x | 13.1 | 1.5 | 899.4% | |
Debt to equity ratio | x | 0 | 1.0 | 1.3% | |
Sales to assets ratio | x | 0.7 | 0.2 | 479.2% | |
Return on assets | % | 9.9 | 6.9 | 144.6% | |
Return on equity | % | 17.0 | 5.4 | 315.6% | |
Return on capital | % | 23.8 | 12.4 | 191.9% | |
Exports to sales | % | 49.6 | 0 | - | |
Imports to sales | % | 18.8 | 0 | - | |
Exports (fob) | Rs m | 97,091 | NA | - | |
Imports (cif) | Rs m | 36,741 | NA | - | |
Fx inflow | Rs m | 97,316 | 15,200 | 640.2% | |
Fx outflow | Rs m | 40,589 | 4,889 | 830.2% | |
Net fx | Rs m | 56,727 | 10,312 | 550.1% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 16,220 | -115,975 | -14.0% | |
From Investments | Rs m | -28,768 | -8,265 | 348.1% | |
From Financial Activity | Rs m | 19,191 | 107,525 | 17.8% | |
Net Cashflow | Rs m | 6,656 | -16,650 | -40.0% |
Indian Promoters | % | 54.1 | 52.9 | 102.3% | |
Foreign collaborators | % | 0.0 | 0.0 | - | |
Indian inst/Mut Fund | % | 8.0 | 4.0 | 198.8% | |
FIIs | % | 27.7 | 26.6 | 104.1% | |
ADR/GDR | % | 0.0 | 0.0 | - | |
Free float | % | 10.2 | 16.5 | 61.8% | |
Shareholders | 69,601 | 93,274 | 74.6% | ||
Pledged promoter(s) holding | % | 8.6 | 0.0 | - |
Compare AUROBINDO PHARMA With: STRIDES PHARMA SCIENCE ELDER PHARMA ALEMBIC SANOFI INDIA NATCO PHARMA
Compare AUROBINDO PHARMA With: MYLAN (US) ACTAVIS (US) ADCOCK INGRAM (S. Africa) TEVA PHARMA (Israel)
On Tuesday, Indian share markets witnessed volatile trading activity and ended lower.
For the quarter ended June 2020, AUROBINDO PHARMA has posted a net profit of Rs 8 bn (up 25.6% YoY). Sales on the other hand came in at Rs 59 bn (up 8.8% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.
For the quarter ended June 2020, PIRAMAL ENTERPRISES has posted a net profit of Rs 5 bn (up 22.1% YoY). Sales on the other hand came in at Rs 29 bn (down 16.2% YoY). Read on for a complete analysis of PIRAMAL ENTERPRISES's quarterly results.
For the quarter ended March 2020, AUROBINDO PHARMA has posted a net profit of Rs 9 bn (up 48.2% YoY). Sales on the other hand came in at Rs 62 bn (up 16.4% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.
For the quarter ended December 2019, AUROBINDO PHARMA has posted a net profit of Rs 7 bn (down 0.5% YoY). Sales on the other hand came in at Rs 58 bn (up 10.1% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.
For the quarter ended December 2019, PIRAMAL ENTERPRISES has posted a net profit of Rs 6 bn (up 11.7% YoY). Sales on the other hand came in at Rs 38 bn (up 9.1% YoY). Read on for a complete analysis of PIRAMAL ENTERPRISES's quarterly results.
More Views on NewsAjit Dayal on how India's vaccine strategy will impact the markets.
In this video I tell you the three Nifty ETFs I think are the best.
Narayana Murthy was one of the first unicorn founders to get the backing of this entity...
There is no stopping this 11-bagger stock from significant upside.
In this video, I'll you what I think is the real reason behind yesterday's market crash.
More